课件：他汀肾脏保护.pptVIP

Dick de Zeeuw教授进一步指出，瑞舒伐他汀的肾脏安全问题不是他汀的“类效应”，因为PLANET研究证实阿托伐他汀和瑞舒伐他汀确实对保护肾脏及肾功能方面有不同的影响。基于此， Dick de Zeeuw教授建议：在临床实践中，如果需要给这类患者进行他汀治疗，则不应给予瑞舒伐他汀治疗。 This open-label,noncomparative, multicenter study assessed efficacy and safety of rosuvastatin 40 mg for 96weeks in 1,380 patients with severe hypercholesterolemia, including heterozygous familial hypercholesterolemia. Figure 1. Study populations by final dose. (A) Main study period. Patients could have had treatment down titrated to rosuvastatin 20 mg at any time during the study or additional lipid-lowering therapy added after 12 weeks; therefore,